Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

RKJ Partners

AUGUST 6, 2017

As a part of the buy-side M&A process, once a buyer selects and decides to pursue an acquisition target, it is essential to reach a level of comfort that the business for sale has a reasonable chance of being successfully acquired. What is Valuation? Valuing a company is not a precise exercise, and best described as an art not a science.

M&A 40

M&A Valuation Mergers and Acquisitions Discounted Cash Flow 40

Software Equity Group

MARCH 18, 2024

The journey can be arduous, from grappling with due diligence, negotiation intricacies, and legal hurdles to managing customer relationships concurrently, driving revenue growth, and fostering innovation. What sets SEG apart from the vast range of sell-side M&A advisors available? Clients opt for SEG for several reasons: 1.

Equities 52

Equities M&A Negotiation Investors 52

Transactional Delights

NOVEMBER 24, 2020

A couple of months prior to the November 2019 official announcement, the companies had been in the public spotlight starting with a short period when it was unclear to observers whether the deal would turn fully hostile [6]. On the subsequent Monday, October 28, TIF was trading at $129.72.

M&A 40

M&A Mergers and Acquisitions IT Shares 40

OfficeHours

OCTOBER 23, 2023

Written by a top OfficeHours Coach; Original article published on October 16, 2023 In today’s world, there is much uncertainty around public markets. However, for private equity investors, this uncertainty represents a unique opportunity to take advantage of investment opportunities in public markets.

Investors 130

Investors Private Equity Equities Investment 130

Deal Law Wire

FEBRUARY 9, 2021

Retail investors are becoming an increasingly significant source of capital on public markets, and dealmakers should be aware of how this development can impact M&A transactions and the decision to go public.

Retail 40

Retail Investors M&A Negotiation 40

The Deal

MAY 25, 2023

Corporate advisers suggest the disclosures could wreak havoc on private merger negotiations by inadvertently outing private merger talks and providing fodder for activist investors agitating for deals. But the rules, which take effect after Oct. For access, log in to TheDeal.com or use the form below to request a free trial.

Shares 52

Shares Negotiation Corporation Mergers 52

Razorpay

JULY 27, 2023

Investment Banking Services Initial Public Offering (IPO) When a privately-owned business wants to become a publicly traded company, it goes through an IPO , or Initial Public Offering. But g oing public is risky – if the public does not respond as well as expected, the business could face huge losses.

Investment Banking 52

Investment Banking Banking Bank Investment 52

Cooley M&A

JANUARY 20, 2022

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JULY 9, 2021

In a string of seminal decisions from 2017 through 2019 ( DFC Global , Dell and Aruba ), the Delaware Supreme Court re-shaped appraisal jurisprudence, in each case by overturning the Court of Chancery for failing to give adequate weight to deal price as the most reliable indicator of fair value. share, a 2.67% increase over the deal price.

Mergers and Acquisitions 52

Mergers and Acquisitions Sale Shares Entertainment 52

Cooley M&A

JANUARY 25, 2023

Tech M&A in 2022 was a tale of two halves. 2] Despite the downtrend, global tech M&A activity in 2022 remained strong relative to pre-pandemic levels and accounted for a record 20% of all global M&A activity. Deal volumes dropped from $531.13 billion [1] during the first half of 2022 to $189.17 trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and stuck with it throughout 2024. Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and stuck with it throughout 2024.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64